Compare Incyte Corporation (INCY) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Western Union Co — how do they compare? Incyte Corporation trades at $117.98 (market cap $23.11B), while Western Union Co trades at $8.37 (market cap $2.71B). The key difference: Incyte Corporation is far larger — about 8.5× Western Union Co's market cap, and Western Union Co pays a 10.85% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | WU | |
|---|---|---|
Market Cap | $23.11B | $2.71B |
Sector | Health | Technology |
52-Week High | $118.52 | $10.28 |
52-Week Low | $67.38 | $7.04 |
Enterprise Value | $19.13B | $2.40B |
Dividend Yield | — | 10.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Western Union (WU) trades at $8.65, down 2.59% on the day, with strong valuation metrics including a P/E of 6.53 and P/S of 0.71. The company maintains profitability with a 10.88% net margin and 47.66% ROE, though Q1 2026 earnings missed expectations. Recent developments include strategic partnerships with Total Wireless and Bybit, and the pending acquisition of Intermex. Technical indicators show mixed signals with bullish moving averages but overbought RSI levels.
WU presents a value opportunity with attractive dividend yield and low valuation multiples, but faces revenue decline and margin pressure. The stock trades above analyst consensus target of $7.83, suggesting limited near-term upside. Key risks include declining traditional remittance business and execution challenges in digital transformation. Institutional sentiment remains cautious with only 12.5% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
